125 related articles for article (PubMed ID: 32253514)
1. Clinically applicable cases of anti-programmed cell death protein 1 immunotherapy for colorectal cancer patients.
Chikatani K; Chika N; Suzuki O; Sakimoto T; Ishibashi K; Eguchi H; Okazaki Y; Ishida H
Surg Today; 2020 Dec; 50(12):1694-1698. PubMed ID: 32253514
[TBL] [Abstract][Full Text] [Related]
2. A Model for Predicting DNA Mismatch Repair-deficient Colorectal Cancer.
Chikatani K; Chika N; Suzuki O; Sakimoto T; Ishibashi K; Eguchi H; Okazaki Y; Ishida H
Anticancer Res; 2020 Aug; 40(8):4379-4385. PubMed ID: 32727766
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
8. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Mismatch Repair Protein Testing on Outcome of Early Staged Colorectal Carcinomas.
Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinicopathological characteristics of mismatch repair-deficient colorectal carcinoma in early onset cases as compared with late-onset cases: a retrospective cross-sectional study in Northeastern Iran.
Goshayeshi L; Ghaffarzadegan K; Khooei A; Esmaeilzadeh A; Rahmani Khorram M; Mosannen Mozaffari H; Kiani B; Hoseini B
BMJ Open; 2018 Aug; 8(8):e023102. PubMed ID: 30166308
[TBL] [Abstract][Full Text] [Related]
14. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
[TBL] [Abstract][Full Text] [Related]
16. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.
Funkhouser WK; Lubin IM; Monzon FA; Zehnbauer BA; Evans JP; Ogino S; Nowak JA
J Mol Diagn; 2012; 14(2):91-103. PubMed ID: 22260991
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases.
Sherman SK; Schuitevoerder D; Chan CHF; Turaga KK
Ann Surg Oncol; 2020 Dec; 27(13):5074-5083. PubMed ID: 32583196
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between mismatch repair proteins status and clinicopathological characteristics in sporadic colorectal cancer patients].
Xiao ZT; Zhang RX; Zhao Y; Peng JH; Lu SX; Zhang HZ; Ding PR; Wu XJ; Lu ZH; Li LR; Wan DS; Pan ZZ; Chen G
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(16):1248-1251. PubMed ID: 28441855
[No Abstract] [Full Text] [Related]
19. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]